176 related articles for article (PubMed ID: 18281779)
21. The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer.
Labianca R; Beretta GD; Mosconi S; Milesi L
Crit Rev Oncol Hematol; 2004 Oct; 52(1):73-80. PubMed ID: 15363468
[TBL] [Abstract][Full Text] [Related]
22. Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin.
Ribas A; Gallardo E; Vera R; Casado S; Vidal R; Bellmunt J
Clin Oncol (R Coll Radiol); 1997; 9(4):269-70. PubMed ID: 9315406
[TBL] [Abstract][Full Text] [Related]
23. [Clinical significance of TS and DPD activities in colorectal carcinoma as a predictive factor of UFT sensitivity].
Funahashi K; Koike J; Saito N; Miki T; Matsumoto H; Ryu M; Shiokawa H; Tokuyama T; Goto T; Teramoto T
Gan To Kagaku Ryoho; 2004 Feb; 31(2):189-93. PubMed ID: 14997749
[TBL] [Abstract][Full Text] [Related]
24. UFT and S-1 for treatment of primary lung cancer.
Tanaka F; Wada H; Fukushima M
Gen Thorac Cardiovasc Surg; 2010 Jan; 58(1):3-13. PubMed ID: 20058135
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change?
Diasio RB
N Engl J Med; 2004 Apr; 350(17):1777-9. PubMed ID: 15103005
[No Abstract] [Full Text] [Related]
26. UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review.
Minsky BD
Int J Cancer; 2001 Feb; 96(1):1-10. PubMed ID: 11241325
[TBL] [Abstract][Full Text] [Related]
27. [Clinical results of UFT against ovarian carcinoma].
Tanaka K; Kodama S; Nakamura M; Takahashi T; Honma S; Maruhashi T; Tokunaga A; Takeuchi Y; Sudou N; Adachi S
Gan To Kagaku Ryoho; 1994 Jul; 21(8):1229-33. PubMed ID: 8031166
[TBL] [Abstract][Full Text] [Related]
28. [A case of good response in a rectal cancer patient with decreased dihydropyrimidine dehydrogenase activity because of strict control of the 5-fluorouracil dose].
Tsukiyama G; Hasegawa M; Yabuki S; Tanaka H; Tanahashi C
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2023-5. PubMed ID: 24394000
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
30. [Tegafur--preoperative treatment with tegafur suppositories for rectal cancer].
Ohwada S; Sato Y; Yoshimura S; Kawate S; Morishita Y; Kashiwabara K
Nihon Rinsho; 2003 Sep; 61 Suppl 7():341-4. PubMed ID: 14574908
[No Abstract] [Full Text] [Related]
31. Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy.
van Kuilenburg AB; Klumpen HJ; Westermann AM; Zoetekouw L; Bakker PJ; Guchelaar HJ; Richel DJ
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):726-32. PubMed ID: 18600532
[TBL] [Abstract][Full Text] [Related]
32. [UFT].
TakuchiT
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1692-6. PubMed ID: 6433802
[No Abstract] [Full Text] [Related]
33. [A case of uterine cervical cancer in which UFT was an effective preoperative treatment].
Nagai N; Oshita T; Shigemasa K; Ohama K; Takehara K; Miyaoka S
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2095-9. PubMed ID: 10584579
[TBL] [Abstract][Full Text] [Related]
34. [Severe Therapy-Related Pancytopenia Caused by UFT and LV in a Patient with Ascending Colon Cancer].
Akiyama T; Yasutomi J; Kusashio K; Matsumoto M; Suzuki T; Iida A; Imamura N; Yoshizumi A; Harano R; Udagawa I; Ohtsuka M
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1399-1401. PubMed ID: 29394647
[TBL] [Abstract][Full Text] [Related]
35. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Saif MW; Elfiky A; Diasio R
Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792
[TBL] [Abstract][Full Text] [Related]
36. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
37. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
[TBL] [Abstract][Full Text] [Related]
38. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
39. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
40. [Effective treatment with oral administration of UFT and leucovorin (Uzel) in a patient with liver metastasis and peritoneal dissemination from cecal cancer].
Mimatsu K; Kawasaki A; Aramaki O; Kuboi Y; Amano S; Oida T
Gan To Kagaku Ryoho; 2008 Apr; 35(4):653-5. PubMed ID: 18408438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
